Treatment Patterns in the Management of Multiple Myeloma in a Colombian HMO During 2015–2023: A Real-World Data Study
Author(s)
Farley Gonzalez, MSc1, Leonardo Jose Enciso Olivera, MD1, Juan Manuel Reyes Sanchez, MSc2, Jair A. Arciniegas, MSc2, Luz E. Perez Jaramillo, MSc1, Andreina J. Alamo, BSc2, Carlos Bello, Pharm1, Mónica García, MSc2, Brigitte Alejandra Alarcon, MD2, Jhon E. Bolaños, MSc, MD1;
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia
1Biociencias-Sura, Medellín, Colombia, 2Pfizer, Bogotá, Colombia
Presentation Documents
OBJECTIVES: To identify treatment patterns in the management of multiple myeloma (MM) in a Colombian Health Maintenance Organization (HMO) between 2015-2023.
METHODS: A retrospective, descriptive cohort study of MM patients from 2015 to 2023 was conducted. Patients with the ICD-10 code C90.0 were included. The index date was when MM was diagnosed, and patients were followed until death, insurance discontinuation, or December 31, 2023, whichever occurred first. Demographics, treatment, and medical care were assessed at the index and during follow-up. Data were extracted from HMO administrative health records. Patients who achieved strict complete response, complete response, very good partial response or partial response were classified as responders.
RESULTS: N=700 patients were included. At diagnosis, approximately 50.5% of these patients presented arterial hypertension, with a median age of 64 years (IQR 16, Q1-Q3: 55-71) and more than half (51.3%) of the patients were at III stage (A or B) of the Durie-Salmon classification. At the last contact, 65% were alive, 51.3% had registered a complete response, and 23.1% had progressed. The most common first-line (1L) treatment was CyBorD (Cyclophosphamide+bortezomib+ dexamethasone) (44.9%), where 85.0% were responders and 13.4% progressed. At 2L (513 patients), autologous transplantation (AT) was the preferred option (n=229, 44.6%); the majority of patients (94.8%) were responders and 5.2% progressed. At 3L (271 patients), AT (18.5%), and lenalidomide-bortezomib-dexamethasone (RVd) (12.5%) were the most common treatment strategies. The proportion of patients with later line data was small (4L = 18.4%, 5L = 8%, 6L = 2.7%, and 7L = 0.6%).
CONCLUSIONS: Patients were in later stages of the disease according to Durie-Salmon, most of them achieved complete response at final contact, and CyBorD was the preferred treatment for first line and AT for the second and third lines.
METHODS: A retrospective, descriptive cohort study of MM patients from 2015 to 2023 was conducted. Patients with the ICD-10 code C90.0 were included. The index date was when MM was diagnosed, and patients were followed until death, insurance discontinuation, or December 31, 2023, whichever occurred first. Demographics, treatment, and medical care were assessed at the index and during follow-up. Data were extracted from HMO administrative health records. Patients who achieved strict complete response, complete response, very good partial response or partial response were classified as responders.
RESULTS: N=700 patients were included. At diagnosis, approximately 50.5% of these patients presented arterial hypertension, with a median age of 64 years (IQR 16, Q1-Q3: 55-71) and more than half (51.3%) of the patients were at III stage (A or B) of the Durie-Salmon classification. At the last contact, 65% were alive, 51.3% had registered a complete response, and 23.1% had progressed. The most common first-line (1L) treatment was CyBorD (Cyclophosphamide+bortezomib+ dexamethasone) (44.9%), where 85.0% were responders and 13.4% progressed. At 2L (513 patients), autologous transplantation (AT) was the preferred option (n=229, 44.6%); the majority of patients (94.8%) were responders and 5.2% progressed. At 3L (271 patients), AT (18.5%), and lenalidomide-bortezomib-dexamethasone (RVd) (12.5%) were the most common treatment strategies. The proportion of patients with later line data was small (4L = 18.4%, 5L = 8%, 6L = 2.7%, and 7L = 0.6%).
CONCLUSIONS: Patients were in later stages of the disease according to Durie-Salmon, most of them achieved complete response at final contact, and CyBorD was the preferred treatment for first line and AT for the second and third lines.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
HSD35
Topic
Health Service Delivery & Process of Care
Disease
SDC: Oncology